Atrial Fibrillation and Acid Reflux Disease

被引：27

作者：

Velagapudi, Poonam ^{[1
]}

Turagam, Mohit K. ^{[1
]}

Leal, Miguel A. ^{[2
]}

Kocheril, Abraham G. ^{[3
]}

机构：

[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA

[2] Univ Wisconsin, Sch Med & Publ Hlth, Cardiac Electrophysiol & Cardiovasc Med Div, Dept Med, Madison, WI 53701 USA

[3] Univ Illinois, Coll Med, Div Cardiac Electrophysiol & Cardiovasc Med, Dept Med, Urbana, IL 61801 USA

来源：

CLINICAL CARDIOLOGY | 2012年 / 35卷 / 03期

关键词：

NEUROCARDIAC FUNCTION; RISK-FACTOR; ESOPHAGITIS; INFLAMMATION; STIMULATION; HEART; PERPETUATION; ARRHYTHMIAS; ABLATION; HUMANS;

D O I：

10.1002/clc.21969

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To date, the precise mechanism of atrial fibrillation (AF) as a possible cause of reflux disease remains uncertain, although some possibilities can be postulated. Inflammation and vagal stimulation may have a key role linking these 2 common diseases. There is some evidence in the form of case reports and limited observational studies reporting that reflux disease, and more specifically esophagitis, can cause paroxysmal AF, and various mechanisms have been proposed. Some studies have demonstrated that acid suppressive therapy by proton pump inhibitors (PPIs) may help ameliorate symptoms associated with AF and also facilitate conversion to normal sinus rhythm in a subset of patients. Further prospective studies are needed to determine if a true causal mechanism exists between the two and assess whether the mechanism is dependent on a specific subtype of AF. In addition, the response of AF-related symptoms to PPI therapy and the potential for PPI therapy to reduce the development of AF merits further investigation. Clin. Cardiol. 2011 DOI: 10.1002/clc.21969

引用

页码：180 / 186

页数：7